10-K: BioRestorative Therapies Faces Going Concern Doubt Amid Losses

BioRestorative Therapies reported a significant net loss and negative cash flow for 2025, raising substantial doubt about its ability to continue as a going concern, despite clinical progress and recent capital raises.

Summary

• BioRestorative Therapies, Inc. (BRTX) reported a net loss of $14.2 million for the year ended December 31, 2025, an increase from $8.98 million in 2024.
• Operating activities resulted in negative cash flow of $10.8 million in 2025, compared to $8.23 million in 2024.
• As of December 31, 2025, the company had a working capital deficit of $0.6 million, a decrease from a surplus of $7.4 million in 2024.
• The company's independent registered public accounting firm expressed substantial doubt about its ability to continue as a going concern for at least twelve months after the financial statements' issuance date.
• BRTX-100, the lead cell therapy candidate for chronic lumbar disc disease (cLDD), received FDA Fast Track designation in February 2025.
• Preliminary 26-, 52-, and 104-week blinded data from the Phase 2 clinical trial for BRTX-100 showed no serious adverse events or dose-limiting toxicity in the first 15 patients.
• New preliminary blinded clinical data from 36 patients in the Phase 2 trial showed over 74% improvement in function and over 72% reduction in pain by 52 weeks, with no serious adverse events.
• The FDA cleared an Investigational New Drug (IND) application for BRTX-100 for chronic cervical discogenic pain in February 2025.
• Enrollment for the Phase 2 clinical trial of BRTX-100 was completed with 99 patients in February 2026.
• The company was granted a Type B meeting with the FDA in December 2025 to discuss a potential accelerated Biologics License Application (BLA) approval pathway for BRTX-100, and has initiated Phase 3 enabling activities.
• Several new patents related to the ThermoStem Program (metabolic disorders) were issued in Europe, Israel, and Japan during 2025, with an Australian patent expected soon.
• The company operates a commercial biocosmeceuticals business, manufacturing a cell-based secretome product, and plans to expand its offering.
• In October 2025, the company raised $1.085 million in gross proceeds from a registered direct public offering of common stock and issued warrants.
• In February 2026, the company raised $5.0 million in gross proceeds from a public offering of common stock and warrants, including pre-funded warrants that were subsequently exercised.
• The company received a Nasdaq notice on March 26, 2026, for non-compliance with the minimum bid price requirement ($1.00 per share) and has 180 calendar days to regain compliance.
• Material weaknesses in internal control over financial reporting were identified, including lack of adherence to formal policies, risk assessment procedures, and effective controls over financial reporting and disclosures.
• The employment agreements for CEO Lance Alstodt and VP of R&D Francisco Silva expired on March 18, 2026, and have not yet been extended.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the explicit 'going concern' doubt, significant financial losses, negative cash flow, and Nasdaq delisting notice, which overshadow the positive clinical and intellectual property developments.

Positives

• BRTX-100 received FDA Fast Track designation for chronic lumbar disc disease, potentially expediting development and review.
• Preliminary Phase 2 clinical trial data for BRTX-100 showed positive results, with over 74% of subjects achieving greater than 50% improvement in function and over 72% reporting greater than 50% pain reduction by 52 weeks, with no serious adverse events.
• FDA cleared an IND application for BRTX-100 for chronic cervical discogenic pain, expanding the potential indications.
• Enrollment of 99 patients in the Phase 2 clinical trial for BRTX-100 was completed in February 2026, a significant milestone.
• Positive official summary from a Type B meeting with the FDA regarding a potential accelerated BLA pathway for BRTX-100, leading to initiation of Phase 3 enabling activities.
• Multiple international patents (Europe, Israel, Japan, Australia) were issued or allowed for the ThermoStem Program, strengthening intellectual property.
• Hired Sandy Lipkins for technology commercialization and business development, and Crystal Romano as Head of Global Commercial Operations, indicating focus on commercialization.
• Received a provisional license from the NYSDOH for processing allogeneic donor tissue material for medical research, expanding laboratory capabilities.

Negatives

• Reported a significant net loss of $14.2 million for the year ended December 31, 2025, an increase from $8.98 million in 2024.
• Experienced negative cash flows from operations of $10.8 million in 2025.
• Working capital deficit of $0.6 million as of December 31, 2025, a substantial decline from a $7.4 million surplus in 2024.
• The independent auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• Current funds are not sufficient to fund development efforts for the next twelve months or attain profitable operations, necessitating significant additional financing.
• Received a Nasdaq notice for non-compliance with the minimum bid price requirement ($1.00 per share), risking delisting.
• Identified material weaknesses in internal control over financial reporting, indicating deficiencies in financial reporting processes.
• Employment agreements for the CEO and VP of R&D expired in March 2026 and have not been extended, creating uncertainty in key leadership roles.
• Royalty revenue decreased from $101,000 in 2024 to $59,700 in 2025, primarily due to a decrease in disc procedures.

Risks

• Substantial doubt about the ability to continue as a going concern due to significant losses and negative cash flows.
• Need to obtain a significant amount of additional financing to complete clinical trials (Phase 2 and contemplated Phase 3 for BRTX-100, and ThermoStem clinical trials) and fund operations.
• Inability to obtain required financing on commercially reasonable terms or otherwise, potentially leading to curtailment or discontinuation of operations.
• High-risk business strategy focused on cellular-based products and services with no assurance of commercial viability, legal protection, operational success, or scientific efficacy.
• Dependence on executive officers (Lance Alstodt, Francisco Silva) whose employment agreements have expired and have not been extended, and the ability to attract and retain additional qualified personnel.
• Potential delays or difficulties in enrolling sufficient patients in clinical trials, which could delay or prevent regulatory approvals.
• Uncertainty in autologous cell therapy development due to inherent variability in cell population from patient to patient, affecting manufacturing and product release.
• Disruption to access to critical media, reagents, devices, materials, and systems from third parties could adversely affect clinical trials and commercial production.
• Clinical trials may fail to demonstrate adequate safety and efficacy, preventing or delaying regulatory approval and commercialization.
• Inability to obtain FDA approval for product candidates in the U.S. or foreign jurisdictions, limiting market potential.
• Lack of manufacturing capabilities to produce product candidates at commercial scale quantities and absence of alternate manufacturing supply.
• Uncertain commercial potential and profitability of products, with high costs of goods for cell therapy products.
• Difficulties in sourcing brown adipose (fat) tissue for the ThermoStem Program.
• Potential for safety problems with new stem cell-based therapies to materially and adversely affect initiatives.
• Vulnerability to competition from pharmaceutical, biotechnology, and medical device companies with greater resources, and from unapproved stem cell therapies.
• Limited experience in cell therapy development and marketing, increasing the risk of unsuccessful business establishment.
• Novel technologies are inherently expensive, risky, and may not be understood or accepted in the marketplace.
• Cell therapy product candidates approved as biologics may face biosimilar competition sooner than anticipated.
• Significant product liability claims and litigation risks, with potentially inadequate insurance coverage.
• Internal computer systems or those of contractors may fail or suffer security breaches, disrupting development programs.
• Inability to obtain reimbursement for products and services from private and governmental insurers could negatively impact demand.
• Activity as a contract manufacturer of biologic-based cosmetics could lead to FDA enforcement actions outside of control, harming reputation or product development.
• Inability to protect proprietary rights through patents, trade secrets, and other agreements, or infringement on others' rights.
• Changes to United States patent law (e.g., AIA, court decisions) may adversely affect intellectual property rights.
• Risk of compulsory licenses in certain countries, diminishing future revenues.
• Products will remain subject to ongoing regulatory oversight even if approved, with potential for restrictions or withdrawal.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, with substantial penalties for non-compliance.
• Uncertainty regarding government, private health insurers, and third-party payor coverage and reimbursement for therapies.
• Potential adverse effects from unintended consequences of healthcare reform in the United States (e.g., PPACA, IRA).
• Competitor companies or hospitals in the EU may use rules permitting sales of unlicensed medicines for individual patients to compete without marketing authorization.
• Inability to comply with Nasdaq's minimum bid price requirement, potentially leading to delisting.
• Significant future issuances or resales of common stock may materially dilute stockholders' ownership and affect market price.
• Common stock classified as a penny stock, potentially resulting in less liquidity.
• Anti-takeover provisions in Nevada law and corporate documents may make it difficult for a third party to acquire control.

Future Outlook

The company anticipates continued net losses and negative cash flows as it executes development plans for 2026 and beyond, requiring significant additional funding. It aims to submit a Phase 3 IND for BRTX-100 during 2026 and explore expanding its biocosmeceutical offerings via IND-enabling studies. The company intends to seek capital through ATM programs, warrant exercises, investment bankers, biotech funds, strategic partners, and other financial institutions. There is no assurance that required financing will be obtained or that goals will be accomplished within projected timeframes.

Management Comments

• We believe that our current funds may not be sufficient for us to complete our Phase 2 clinical trial investigating the use of BRTX-100 in the treatment of chronic lower back pain arising from degenerative disc disease, continue our pre-clinical research and development efforts with respect to our ThermoStem Program and satisfy our current working capital needs through the end of the 12 month period following the date of the financial statements included in this Annual Report.
• The implementation of our business plan, as discussed below, will require the receipt of significant additional financing to fund our research and development efforts, including our contemplated Phase 3 clinical trial with regard to BRTX-100 and our contemplated clinical trials relating to our ThermoStem Program, and otherwise fund our operations.
• We intend to seek to raise capital through our 2024 ATM and warrant exercises as well as through investment bankers and from biotech funds, strategic partners and other financial institutions.

Industry Context

StockSavvy.ai notes that BioRestorative Therapies operates in the highly competitive and capital-intensive regenerative medicine and cell therapy space. The company's focus on autologous mesenchymal stem cells for disc/spine conditions (BRTX-100) and brown adipose-derived stem cells for metabolic disorders (ThermoStem) positions it within innovative, yet nascent, therapeutic areas. The FDA's Fast Track designation for BRTX-100 is a positive signal, indicating recognition of unmet medical need, but the regulatory pathway for novel cell therapies remains complex and lengthy. The biocosmeceuticals segment, while generating some revenue, is a smaller part of the business. The increasing competition in the obesity market, particularly from GLP-1 receptor agonists like Wegovy and Ozempic, presents a significant challenge for the ThermoStem program, which aims to address similar conditions. The ongoing FDA enforcement against unapproved stem cell therapies highlights the regulatory scrutiny in this sector, which could both legitimize approved products and create competition from non-compliant clinics.

Comparison to Industry Standards

• BRTX-100's autologous cell approach is highlighted as having low to no risk of rejection and a greater safety profile compared to allogeneic therapies, which is a competitive advantage in the stem cell field.
• The hypoxic culturing process for BRTX-100 is claimed to create increased cell proliferation, greater plasticity, enhanced paracrine effect, and improved cell survival, differentiating it from standard MSC culturing methods.
• The company believes BRTX-100 has competitive advantages over Mesoblast's adult stem cell biologic due to its autologous nature and hypoxic culturing, which are critical factors in cell therapy development.
• The anticipated cost of a single BRTX-100 treatment is expected to compare favorably to conservative treatments (e.g., oral medications $1,000-$2,000/year, injections $8,000/year, physical therapy $20,000/year) and be less expensive than common surgical procedures (e.g., spinal fusion $110,000, discectomy $20,000-$50,000, disc replacement $80,000-$150,000).
• The company faces competition from established pharmaceutical companies like Novo Nordisk, Sanofi, Merck, Eli Lilly, Roche, Pfizer, Regeneron, and Altimmune in the obesity and diabetes market, which have substantially greater financial and R&D resources.
• The recent launch of FDA-approved oral Wegovy in January 2026 significantly increases competition in the obesity market, posing a challenge for the ThermoStem Program's market penetration.

Management Changes

Corporate Governance

Related Party Transactions

• Auctus Fund, LLC (Auctus) holds warrants for the purchase of up to 3,042,256 shares of common stock, subject to a 9.99% beneficial ownership limitation. As of March 23, 2026, Auctus owned 1,419,536 shares of common stock (5.6%) and warrants exercisable for 1,250,675 shares.
• In February 2026, Auctus converted its remaining 1,398,158 shares of Series B Preferred Stock into common stock, and received 918,055 shares of common stock in full satisfaction of Abeyance Shares (shares previously paid for but held due to beneficial ownership limitations).

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises, potential negative impact on share price from Nasdaq delisting notice, and uncertainty regarding the company's ability to continue as a going concern. The stock repurchase program, if executed, could provide some support.
• **Employees**: Potential uncertainty regarding the future of the company due to going concern doubt and the expiration of employment agreements for key executives. Stock-based compensation is a significant part of executive pay, linking their interests to share performance.
• **Customers**: For biocosmeceuticals, continued product availability and quality are key. For future therapeutic products, successful regulatory approval and commercialization are necessary to benefit patients.
• **Creditors**: The going concern doubt and working capital deficit indicate increased risk for creditors.
• **Regulatory Authorities (FDA, Nasdaq)**: The company is actively engaged with the FDA on clinical trials and BLA pathways, and is addressing Nasdaq's listing compliance issues. Non-compliance could lead to delisting.

Next Steps

• Initiate Phase 3 enabling activities for the BRTX-100 program with the goal of submitting a Phase 3 IND during 2026.
• Explore the potential of expanding the commercial biocosmeceutical offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies.
• Undertake additional preclinical animal studies for the ThermoStem Program to optimize delivery and explore targeting additional indications.
• Monitor the closing bid price of common stock and consider options, including a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement by September 22, 2026.
• Continue implementing measures to remediate identified material weaknesses in internal control over financial reporting.
• Negotiate an extension of the Melville Lease for principal executive offices and laboratory.

Key Dates

Recommendation

The company's explicit disclosure of 'substantial doubt about our ability to continue as a going concern,' coupled with a significant increase in net loss, negative cash flow from operations, and a deteriorating working capital position, presents an extremely high-risk investment profile. The Nasdaq delisting notice further compounds these concerns, indicating a severe erosion of market confidence and potential liquidity issues. While there are positive clinical developments for BRTX-100, the financial instability and the need for substantial additional financing without clear assurance of obtaining it, make the stock a 'strong sell' for seasoned investors. The expiration of key executive employment agreements adds another layer of uncertainty to leadership stability.

Keywords

Stem Cell Therapy, Degenerative Disc Disease, BRTX-100, Biologics, Phase 2 Clinical Trial, Chronic Lower Back Pain, Metabolic Disorders, ThermoStem, Biocosmeceuticals, FDA Fast Track, IND Clearance, Nasdaq Delisting, Going Concern, Capital Raise, Biotechnology, Regenerative Medicine, Autologous Cells, Hypoxic Culturing, Patents, Corporate Governance, Internal Controls